<DOC>
	<DOCNO>NCT02707640</DOCNO>
	<brief_summary>This Phase 2 , randomize , double-blind , placebo-controlled safety tolerability study N-acetylcysteine placebo participant mild moderate idiopathic pulmonary fibrosis ( IPF ) receive background pirfenidone therapy .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability N-Acetylcysteine When Administered With Pirfenidone Participants With Idiopathic Pulmonary Fibrosis ( IPF )</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Pirfenidone</mesh_term>
	<criteria>Clinical symptom consistent IPF &gt; =3 month ' duration ( relative Day 1 ) Must dose pirfenidone less 1602 mg/day least 8 week prior randomization Day 1 Able understand importance adherence study treatment study protocol willing follow study requirement , include concomitant medication restriction , throughout study Women childbearing capacity require negative serum pregnancy test treatment must agree maintain highly effective contraception practice abstinence use least two method birth control date consent end study Diagnosis usual interstitial pneumonia ( UIP ) IPF highresolution compute tomography ( HRCT ) surgical lung biopsy . Previous HRCT scan , typically available , one point time diagnosis one recent , make last year study inclusion , use assessed central Reading Committee Significant clinical worsening IPF screen Day 1 study , opinion investigator Unlikely comply requirement study , opinion investigator Patientreported cigarette smoking within 3 month screen unwilling avoid use tobacco product throughout study History clinically significant environmental exposure know cause pulmonary fibrosis ( PF ) , include limited drug ( amiodarone ) , asbestos , beryllium , radiation , domestic bird Known cause interstitial lung disease , include limited radiation , drug toxicity , sarcoidosis , hypersensitivity pneumonitis , cryptogenic organize pneumonia Clinical diagnosis connective tissue disease , include limited scleroderma , polymyositis/dermatomyositis , systemic lupus erythematosus , rheumatoid arthritis Clinical evidence active infection , include limited bronchitis , pneumonia , sinusitis , urinary tract infection , cellulitis ( diffuse inflammation connective tissue skin ) Any history malignancy likely result significant disability likely require significant medical surgical intervention within next 6 month ( relative Day 1 ) . This include minor surgical procedure localize cancer ( e.g. , basal cell carcinoma , squamous skin carcinoma ) History severe hepatic impairment endstage liver disease History endstage renal disease require dialysis History unstable deteriorate cardiac pulmonary disease ( IPF ) within previous 6 month ( relative Day 1 ) Any condition , opinion investigator , may significantly exacerbate known side effect associate administration Nacetylcysteine take single medication Suspected intolerance , allergy , hypersensitivity pirfenidone component Known intolerance , allergy , hypersensitivity Nacetylcysteine component</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>